Cypherpunk Technologies Inc.
Moat Score — Cypherpunk Technologies Inc.
Total Moat Score
2 / 30
| Moat Factor | Score | Analysis |
|---|---|---|
| Intangible Assets Patents, trademarks, brand strength, or regulatory licenses that protect a company's products or services from being freely copied by competitors. | 1 / 5 | The treasury strategy itself carries no intellectual property, and the legacy Leap Therapeutics oncology assets have some underlying clinical IP but are not the market's current focus and were not highlighted as a protected moat in the pivot. Overall intangible protection is thin and mostly inherited from the pre-pivot business. |
| Cost Advantage A durable ability to produce goods or services more cheaply than competitors — through scale, unique access to cheap inputs, location, or process — that lets a company undercut rivals or out-earn them at the same price. | 0 / 5 | Accumulating Zcash offers no structural cost advantage over any other buyer purchasing ZEC on the open market, and the small, six-employee organization has no manufacturing or operating scale advantage in either the treasury or oncology business. |
| Pricing Power The ability to raise prices without losing meaningful business, because the product or service is differentiated, mission-critical, or has few good substitutes. | 0 / 5 | The treasury business has no pricing power since its value is purely a mark-to-market function of ZEC's market price, and the oncology subsidiary is pre-revenue with no product on the market to price. |
| Network Effect The product or service becomes more valuable to every user as more people or organizations use it, making an established leader harder to displace. | 0 / 5 | Zcash as a protocol may benefit from network effects among its users, but those effects accrue to the cryptocurrency and its ecosystem, not specifically to Cypherpunk as a corporate holder of the asset, so no company-level network effect exists. |
| Switching Costs The money, time, or operational disruption a customer would face switching to a competitor, which locks in existing customers and supports renewals. | 0 / 5 | There are no switching costs in either business line: investors can freely buy ZEC directly or through other vehicles instead of CYPH shares, and the oncology program has no customers or prescribers yet to be locked in. |
| Efficient Scale A market that can only profitably support a small number of players, so incumbents face limited threat from new entrants even without other defenses. | 1 / 5 | Being an early, Winklevoss-backed mover specifically targeting a Zcash treasury niche gives Cypherpunk a modest head start in a narrow category most other digital-asset treasury companies have not pursued, but the niche is small, unproven, and easily contestable by better-capitalized entrants. |